Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader
in tubeless
insulin pump technology with its Omnipod® Insulin
Management System (Omnipod System), today announced positive results
from the first feasibility study of the Omnipod Horizon™ hybrid
closed-loop system. The study demonstrated that the Omnipod automated
glucose control algorithm performed well, was safe during the day and
night for adults with type 1 diabetes, and was very effective at night
with minimal hypoglycemia and excellent fasting glucose. These data were
presented today at the 10th International Conference on
Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France.
Additional studies are underway to further validate the performance in
adult and pediatric populations.

Study participants included 24 adults with type 1 diabetes. The 36-hour
study1 included a modified version of Insulet's Omnipod, a
Dexcom® continuous glucose sensor, and Insulet's personalized
model predictive control algorithm. Results showed use of the Company's
hybrid closed-loop system was associated with significantly less time
spent in hypoglycemic blood glucose range compared to ranges prior to
the study. Key findings included patients achieving and remaining in the
target blood glucose control range 69% of the time over the course of
the study and maintaining target blood glucose control 90% of the time
during the overnight period.

"These very positive results, particularly in the overnight period,
demonstrate the potential for the Omnipod Horizon System to improve
clinical outcomes in patients with type 1 diabetes," said Dr. Bruce
Buckingham, Professor of Pediatric Endocrinology at the Lucille Salter
Packard Children's Hospital, Stanford University, and Principal
Investigator of the study. "This is a safe system providing significant
reductions in hypoglycemia both during the day and night, and the system
made significant improvements in overnight glucose control, decreasing
glucose variability and bringing fasting glucose values into range.
These are very positive early findings and I think I speak for the
entire team when I say I am excited to see how the Horizon system
continues to perform in future clinical studies."

"We are incredibly excited by the early results of this trial, which
demonstrated excellent glucose control and tremendous promise to make a
significant impact for patients," said Shacey Petrovic, President and
Chief Operating Officer. "Omnipod allows our users to feel more
confident, and to experience improved quality of life and outcomes,and
we are thrilled our Omnipod Horizon System is already demonstrating the
ability to continue to make a significant impact on improving the lives
of people with diabetes."

The Omnipod® Insulin Management System is an innovative
continuous insulin delivery system that provides all the proven benefits
of continuous subcutaneous insulin infusion (CSII) therapy in a way no
conventional insulin pump can. The Omnipod System's innovative design
and features allows people living with diabetes to live their life-and
manage their diabetes-with unprecedented freedom, comfort, convenience,
and ease. The Omnipod System consists of two components: (i) a Pod that
stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM)
that wirelessly programs the user's personalized insulin delivery,
calculates suggested doses and insulin on board, and has a convenient,
built-in blood glucose meter. The small, light-weight Pod can be worn in
multiple locations, including the abdomen, hip, back of upper arm, upper
thigh or lower back and, because it is waterproof (IPX8), there is no
need to remove when showering, swimming or performing other activities.
This means that Omnipod can provide up to three days of non-stop insulin
delivery, without the need to disconnect a tube set or manually inject
insulin. The Pod and PDM communicate wirelessly to offer precise,
personalized and continuous insulin delivery with customizable basal and
bolus delivery options, as well as important safety checks. The Pod's
auto-cannula insertion is quick, simple, and virtually pain-free. Users
never have to handle a needle. The user simply pushes a button on the
PDM and the Pod's automated insertion system inserts the cannula beneath
the skin and begins delivering insulin according to the user's
programmed basal rate.

The Omnipod System is the world's first commercially available tubeless
insulin delivery system that allows users to live untethered by tubing
and without the stress and anxiety of multiple daily injections. By
breaking down the barriers to insulin pump therapy, the Omnipod System
offers freedom for users to live life on their own terms and with the
ease of use they deserve.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device
company dedicated to making the lives of people with diabetes easier.
Through its Omnipod Insulin Management System, Insulet seeks to expand
the use of insulin pump therapy among people with insulin-dependent
diabetes. The Omnipod is a revolutionary and easy-to-use tubeless
insulin pump that features just two parts and a fully-automated cannula
insertion. Insulet's Delivery Systems business also partners with global
pharmaceutical and biotechnology companies to tailor the Omnipod
technology platform for the delivery of subcutaneous drugs across
multiple therapeutic areas. Founded in 2000, Insulet Corporation is
based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations, intentions, beliefs or
strategies regarding the future. These forward-looking statements are
based on its current expectations and beliefs concerning future
developments and their potential effects on Insulet. There can be no
assurance that future developments affecting Insulet will be those that
it has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 29, 2016 in the section entitled
"Risk Factors," and in its other filings from time to time with
the Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its assumptions
prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.